IRTUM – Institutional Repository of the Technical University of Moldova

Influence of CYP2C19*2 Polymorphism on Clinical Outcomes in Moldova’s Patients Treated with Clopidogrel After Percutaneous Coronary Intervention

Show simple item record

dc.contributor.author DOGOT, Marta
dc.contributor.author GALEA-ABDUSA, Daniela
dc.contributor.author BUZA, Anastasia
dc.contributor.author GRIB, Andrei
dc.contributor.author CUROCICHIN, Ghenadie
dc.contributor.author VATAMAN, Eleonora
dc.contributor.author CAPROS, Natalia
dc.date.accessioned 2023-11-10T06:51:02Z
dc.date.available 2023-11-10T06:51:02Z
dc.date.issued 2023
dc.identifier.citation DOGOT, Marta, GALEA-ABDUSA, Daniela, BUZA, Anastasia et al. Influence of CYP2C19*2 Polymorphism on Clinical Outcomes in Moldova’s Patients Treated with Clopidogrel After Percutaneous Coronary Intervention. In: 6th International Conference on Nanotechnologies and Biomedical Engineering: proc. of ICNBME-2023, 20–23, 2023, Chisinau, vol. 1: Nanotechnologies and Nano-biomaterials for Applications in Medicine, 2023, p. 528-536. ISBN 978-3-031-42774-9. e-ISBN 978-3-031-42775-6. en_US
dc.identifier.isbn 978-3-031-42774-9
dc.identifier.isbn 978-3-031-42775-6
dc.identifier.uri https://doi.org/10.1007/978-3-031-42775-6_56
dc.identifier.uri http://repository.utm.md/handle/5014/24743
dc.description Acces full text - https://doi.org/10.1007/978-3-031-42775-6_56 en_US
dc.description.abstract This study evaluated the effect of genetic polymorphism in CYP2C19*2 on clinical response in Moldova’s patients treated with clopidogrel after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). A total of 172 coronary patients after PCI were treated with clopidogrel and aspirin for at least 6–12 months; we recorded major adverse cardiac events (MACE) within 6–12 months. The CYP2C19 polymorphisms were evaluated using TaqMan genotyping procedure. During a 6–12 months follow-up, the CYP2C19*2 carriers had an odds of cardiac death of 4.42 (95% CI 1.68, 11.65), of myocardial infarction of 8.69 (95% CI 2.95, 25.53), of stent thrombosis of 11.4 (95% CI 1.15, 112.98), and of unstable angina by 3.47 (95% CI 1.316, 9.149) compared with non-carriers (p < .001). The CYP2C19*2 gene polymorphism modulates the drug efficacy of clopidogrel in patients undergoing PCI and further enhance the risk of MACE. Clinical testing of CYP2C19 genotype can be used to personalize the selection of antiplatelet therapy and reduce the risk of major adverse cardiovascular events. en_US
dc.language.iso en en_US
dc.publisher Springer Nature Switzerland en_US
dc.rights Attribution-NonCommercial-NoDerivs 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.subject polymorphisms en_US
dc.subject percutaneous coronary interventions en_US
dc.subject clopidogrel en_US
dc.title Influence of CYP2C19*2 Polymorphism on Clinical Outcomes in Moldova’s Patients Treated with Clopidogrel After Percutaneous Coronary Intervention en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

  • 2023
    6th International Conference on Nanotechnologies and Biomedical Engineering, September 20–23, 2023, Chisinau, Moldova

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Search DSpace


Browse

My Account